Sharemaestro company-news research for CAMP4 THERAPEUTICS CORPORATION (CAMP), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest CAMP news and sentiment
CAMP4 THERAPEUTICS CORPORATION
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score49Neutral is 50
Early balanced news score
19/100 evidence confidence
100% direct company focus
15 current stories across 7 publishers
Current company news
Early balanced news score
15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone37/100
→
Published 30-day score49/100
Latest source headline
Camp4 Therapeutics at Cantor conference: pushing first SYNGAP1 trial
Investing.com · 10 Sep 2026 16:28
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
15 current stories are mapped specifically to CAMP.
The score uses 7 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.111.
Confidence is 19/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
100%/100
Company news15 company stories
85/100
Story agreement15/100 difference
News history
Daily score and story count over 30 days
19 Aug03 Sep17 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.111 after freshness weightingSource breadth100
7 independent publishersCompany relevance100
share tied directly to this companyFreshness15
recency-weighted evidenceAgreement85
how closely stories agreePublisher mix67
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks19 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
20 Mar16 Jun11 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
11 Sep 202649USD 4.25-3.6%
04 Sep 202646USD 4.41+6.3%
28 Aug 202643USD 4.15-7.4%
21 Aug 202644USD 4.48-17.6%
14 Aug 202644USD 5.44+28.3%
07 Aug 202650USD 4.24+22.9%
31 Jul 202650USD 3.45+9.2%
24 Jul 202646USD 3.16-14.8%
Provisional evidence
News subjects
What is shaping the score
Earnings315 stories · 33%
Market update545 stories · 33%
Analyst action592 stories · 13%
Deals and strategy381 stories · 7%
Regulatory and legal501 stories · 7%
Guidance501 stories · 7%
Source mix
Where the evidence comes from
Investing.com505 stories · 33%
MT Newswires502 stories · 13%
GlobeNewswire502 stories · 13%
Stock Titan502 stories · 13%
vinanet.vn131 stories · 7%
dars.gov.et251 stories · 7%
GuruFocus381 stories · 7%
Recurring subjects
Subjects appearing most often
Life Sciences10Financial Markets7Finance6Earnings3
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
07 May50 neutral17 Sep 05:09
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 17 Sep 05:09 | 49 | +1 | 23/100 (-7) | 15 (-12) | Provisional |
| 10 Sep 23:59 | 48 | +1 | 30/100 (+5) | 27 (+1) | Provisional |
| 08 Sep 23:59 | 47 | +1 | 25/100 (-9) | 26 (0) | Provisional |
| 04 Sep 23:59 | 46 | -3 | 34/100 (+2) | 26 (-4) | Provisional |
| 03 Sep 23:59 | 49 | +4 | 32/100 (+3) | 30 (-3) | Provisional |
| 01 Sep 23:59 | 45 | +5 | 29/100 (-7) | 33 (-17) | Provisional |
| 24 Aug 23:59 | 40 | -4 | 36/100 (0) | 50 (-1) | Measured |
| 21 Aug 23:59 | 44 | +0 | 36/100 (+3) | 51 (+2) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#156Tone
Investing.comDirect company coverageStored article
Camp4 Therapeutics at Cantor conference: pushing first SYNGAP1 trial
Camp4 Therapeutics presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, detailing its lead SYNGAP1 program for a rare genetic disease. The company announced regulatory approvals to begin its Phase I/IIa study in Australia, Argentina, and the UK, with the FDA review still pending, and plans to start the trial in Q4 2024. Camp4 emphasized its regRNA platform's ability to upregulate gene expression for haploinsufficient diseases and highlighted a collaboration with GSK for two non-DEE targets, while focusing on SYNGAP1 and related developmental and epileptic encephalopathies.
Financial MarketsLife Sciences
- Published
- 10 Sep 2026 16:28
- News subject
- Market update
- Why this score
- Regulatory Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 9% of the score · 7.1d old
- Duplicates
- 1 consolidated
#2—Not directional
Investing.comDirect company coverageStored article
CAMP4 receives UK authorization for SYNGAP1 trial of CMP-002
CAMP4 Therapeutics Corporation has received authorization from the UK’s Medicines and Healthcare products Regulatory Agency to include UK sites in its Phase 1/2 clinical trial for CMP-002, a treatment for SYNGAP1-related disorder. This expands the trial's geographic scope, following approvals in Australia and Argentina, with clinical trials expected to start in Q4 2026. CMP-002 is an antisense oligonucleotide designed to increase SYNGAP1 gene expression and restore SYNGAP protein levels in patients with this rare central nervous system disorder.
Life Sciences
- Published
- 10 Sep 2026 13:08
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.2d old
- Duplicates
- 2 consolidated
#3—Not directional
MT NewswiresDirect company coverageScored from headline
CAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UK
- Published
- 10 Sep 2026 12:06
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.3d old
- Duplicates
- 1 consolidated
#4—Not directional
GlobeNewswireDirect company coverageStored article
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
CAMP4 Therapeutics will host a virtual Analyst Day on September 28, 2026, to discuss CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder. The event will feature presentations from executive leadership, patient advocates, and a leading KOL, covering the unmet clinical need, trial design for CMP-002's Phase 1/2 study, and updates on the company's early discovery pipeline. CMP-002 aims to restore SYNGAP protein levels in patients with this rare CNS disorder.
FinanceLife Sciences
- Published
- 08 Sep 2026 20:05
- News subject
- Analyst action
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.9d old
- Duplicates
- 1 consolidated
#525Tone
dars.gov.etDirect company coverageScored from headline
CAMP Q2 2026 Earnings: Narrow EPS Miss Leaves Shares Flat as Pre-Commercial Investment Continues - Profit Cycle Analysis
- Published
- 04 Sep 2026 16:46
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 57/100
- 30-day weight
- 31.4% of the score · 13.1d old
- Duplicates
- 1 consolidated
#665Tone
Investing.comDirect company coverageStored article
Camp4 CFO Kelly Gold buys $39,600 in company stock
Camp4 Therapeutics CFO Kelly Gold purchased 10,000 shares of company stock for $39,600, despite the stock's recent decline of 8% but overall yearly gain of 170%. This transaction coincides with positive analyst upgrades and new coverage for Camp4, and Gold's appointment to X4 Pharmaceuticals' board of directors. InvestingPro analysis suggests the stock is undervalued.
Financial MarketsLife Sciences
- Published
- 03 Sep 2026 21:32
- News subject
- Analyst action
- Why this score
- Institutional or insider buying, Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 10.6% of the score · 13.9d old
- Duplicates
- 1 consolidated
#7—Not directional
GlobeNewswireDirect company coverageScored from headline
CAMP4 to Participate in Upcoming Investor Conferences
- Published
- 01 Sep 2026 20:05
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.9d old
- Duplicates
- 1 consolidated
#842Tone
Investing.comDirect company coverageStored article
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock
Camp4 Therapeutics director Andrew J. Schwab sold 400,000 shares of common stock for $1.616 million on August 27, 2026. This sale occurred despite the company's stock being up 161% over the past year, though it declined 11% in the week prior. The company, which analysts suggest is slightly undervalued, recently saw Kelly Gold of Camp4 Therapeutics join X4 Pharmaceuticals' board and received upgraded stock ratings from JPMorgan and Chardan.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 01 Sep 2026 18:34
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 26.9% of the score · 16.0d old
- Duplicates
- 1 consolidated
#913Tone
vinanet.vnDirect company coverageScored from headline
CAMP4 (CAMP) Earnings Snapshot: The EPS Result Is Below Expectation for the Current Session; Price Reaction: The Stock Gains 0.45% on the Day - Dividend Cut Risk
- Published
- 24 Aug 2026 04:47
- News subject
- Earnings
- Why this score
- Missed expectations, Dividend Cut, Deteriorating financial comparison
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 67/100
- 30-day weight
- 10.9% of the score · 24.6d old
- Duplicates
- 1 consolidated
#10—Not directional
Intellectia AIDirect company coverageStored article
CAMP Technical Analysis & ETF Price Forecast
This article provides a technical analysis and price forecast for CAMP4 Therapeutics Corp (CAMP). It presents various technical indicators, including moving averages, RSI, MACD, and support/resistance levels. The overall technical sentiment for CAMP is currently rated as Neutral, despite several moving average indicators suggesting a Buy signal.
Financial MarketsLife Sciences
- Published
- 24 Aug 2026 01:44
- News subject
- Guidance
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.7d old
- Duplicates
- 1 consolidated
#1142Tone
MT NewswiresDirect company coverageScored from headline
Camp4 Therapeutics Insider Sold Shares Worth $879,719, According to a Recent SEC Filing
- Published
- 21 Aug 2026 21:04
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- <0.1% of the score · 26.9d old
- Duplicates
- 1 consolidated
#1238Tone
GuruFocusDirect company coverageStored article
Balyasny Asset Management L.P. Reduces Stake in Camp4 Therapeuti
Balyasny Asset Management L.P. has reduced its stake in Camp4 Therapeutics Corp (CAMP) by 1.57%, selling 41,340 shares at $4.37 each. Despite the reduction, Balyasny still holds a 4.99% stake in Camp4, indicating a cautious but continued interest in the biopharmaceutical company. Camp4 Therapeutics faces significant financial challenges, with a low GF-Score and negative profitability metrics, making it a high-risk investment despite its potential in RNA-based therapeutics.
FinanceFinancial MarketsLife Sciences
- Published
- 21 Aug 2026 00:41
- News subject
- Deals and strategy
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 41/100
- 30-day weight
- 11.2% of the score · 27.7d old
- Duplicates
- 1 consolidated
#13—Not directional
Investing.comDirect company coverageStored article
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock
Daniel Tardiff, CSO of Camp4 Therapeutics, sold 1,738 shares of company stock for $8,272 on August 19, 2026. This transaction follows a 202% return for Camp4 shares over the past year, though the stock is near its Fair Value estimate according to InvestingPro. The company's strong balance sheet and recent analyst upgrades, including JPMorgan's move to Overweight, highlight growing interest in its biotechnology endeavors.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 20 Aug 2026 15:40
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.1d old
- Duplicates
- 2 consolidated
#14—Not directional
Stock TitanDirect company coverageStored article
Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales
Polaris-affiliated funds and individuals have filed an amended Schedule 13D/A for Camp4 Therapeutics (NASDAQ: CAMP), indicating a diluted ownership stake. This reduction is due to Camp4's sales of additional common shares, decreasing the reporting persons' aggregate percentage ownership by over 1% since the previous amendment. Board member Amir Nashat is now deemed to beneficially own approximately 6.3% of Camp4's outstanding common stock through these Polaris entities.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 19 Aug 2026 22:40
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.8d old
- Duplicates
- 1 consolidated
#1540Tone
Stock TitanDirect company coverageStored article
Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares
An affiliate of Camp4 Therapeutics (NASDAQ: CAMP), Daniel Tardiff, plans to sell 1,738 shares of common stock through J.P. Morgan Securities LLC. The proposed sale is valued at approximately $8,275.55 with an anticipated sale date of August 19, 2026. This notice, filed as a Form 144, also indicates a previous 434-share ESPP issuance to Tardiff on July 2, 2026.
FinanceLife Sciences
- Published
- 19 Aug 2026 14:41
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- <0.1% of the score · 29.2d old
- Duplicates
- 1 consolidated
Earlier company news
CAMP news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 76 older CAMP headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to CAMP, but the headline and available text are not mainly about CAMP4 THERAPEUTICS CORPORATION. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of CAMP sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.